Awareness and the potentials NASH in Patients With HIV
NASH in Patients With HIV
PAC’s Journey to 400K Takes the Main Stage at the Country's First National HIV Conference of the Year - POZ
THTX seems to be sponsoring events related to HIV and PLWH who are also suffering from NASH.
It doesn’t sound like they are dropping NASH all together on the contrary they are providing grants for these continuing education and professional developments targeting the physicians in order to create more awareness. They might have been quite conservative about information flow related to the oncology program for whatever reason but not NASH. The futility trial costing estimated $40 millions lasting 18 months won’t need to be funded in advance but gradually. As for oncology trial If the phase 1a/b show any signs of tumour regression or/and progression free survival with a tolerated dose that is quite significant for late stage cancers. The tolerated dose for these patients as we have seen with other targeted drug delivery candidates seems to be less mortality due to adverse effects. Point is the it seems like there is a risk reward equation for late stage cancers, as long as there is some efficacy the more severe adverse effects are more acceptable since that is the only option these patients have. These targeted delivery trials for stage 3/4 cancers with no other treatment options seems to be progressing despite those adverse effects meaning the bar is quite low so I believe TH1902 will progress to phase1b and behind despite possibly some severe adverse effects as long as there is some signs of efficacy or/and absent efficacy it shows decent safety profile moving on to the next stage of the trial chasing efficacy results.
A partnership deal could be reached based on both scenarios early in the process similar to Sutro’s deal after their phase1a results. That potential deal will postpone any need for fund raising so they can move on with both oncology and NASH in the near term. How would this hypothesis effect the valuation my take is positively with a bit more effective communication with the market so the perception will be we don’t need money in the immediate future we managed to close a deal early on for oncology due to promising clinical and financial prospects.
If they manage to get any bites for NASH as well that would be the ideal situation. So there are few scenarios which can deal with the cash issue and depressed valuation if and when things go in right direction and the company manages to take advantage of those opportunities.